Short Interest in GeoVax Labs Inc. (NASDAQ:GOVX) Declines By 61.9%

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 57,276 shares, a drop of 61.9% from the July 15th total of 150,485 shares. Based on an average trading volume of 220,342 shares, the short-interest ratio is presently 0.3 days. Approximately 1.7% of the shares of the company are short sold.

Institutional Investors Weigh In On GeoVax Labs

Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in shares of GeoVax Labs during the 1st quarter valued at $27,000. HRT Financial LP acquired a new stake in shares of GeoVax Labs in the fourth quarter valued at $31,000. Renaissance Technologies LLC bought a new position in GeoVax Labs during the fourth quarter valued at about $104,000. Armistice Capital LLC bought a new position in GeoVax Labs during the third quarter valued at about $253,000. Finally, Ieq Capital LLC acquired a new position in GeoVax Labs during the second quarter worth about $1,352,000. 6.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Wall Street Zen upgraded shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, GeoVax Labs currently has a consensus rating of “Reduce” and a consensus price target of $150.00.

GeoVax Labs Stock Up 0.0%

GeoVax Labs stock traded up $0.00 during trading hours on Friday, hitting $0.72. 197,033 shares of the company traded hands, compared to its average volume of 186,596. GeoVax Labs has a 1-year low of $0.64 and a 1-year high of $20.00. The firm has a market cap of $2.49 million, a P/E ratio of -0.06 and a beta of 3.73. The firm’s 50-day simple moving average is $1.03 and its two-hundred day simple moving average is $1.53.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Monday, July 27th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.16) by $1.19. On average, equities research analysts predict that GeoVax Labs will post -4.94 earnings per share for the current year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.